Tech News
Back to home
Technology

The first human test of a rejuvenation method will begin “shortly”

Source

MIT Technology Review

Published

TL;DR

AI Generated

A Boston startup, Life Biosciences, is set to conduct the first human trial of a rejuvenation method called "reprogramming" to treat eye disease. The technique involves resetting epigenetic controls in cells to restore a healthier state. The trial will involve injecting reprogramming genes into the eyes of patients with glaucoma, with the genes controlled by a genetic switch activated by an antibiotic. While the approach has shown promise in animals, there are concerns about potential risks, including cancer. The company's ultimate goal is to explore the potential for whole-body rejuvenation, but for now, the trial serves as a proof of concept for age reversal.

Read Full Article

Similar Articles

MIT Technology Review

Exclusive eBook: Inside the stealthy startup that pitched brainless human clones

The exclusive eBook delves into R3 Bio, a startup proposing brainless human clones as backup bodies for longevity. The startup's ethically charged vision raises concerns about cloning ethics. The eBook, available only to subscribers, explores the controversial pursuit of human longevity through cloning. Antonio Regalado's work sheds light on the startup's startling concept and its potential implications.

MIT Technology Review•
MIT Technology Review

The Download: murderous ‘mirror’ bacteria, and Chinese workers fighting AI doubles

Scientists initially proposed creating mirror bacteria with reversed proteins and sugars for research purposes, but now fear these organisms could pose a catastrophic threat to life on Earth. In China, tech workers are concerned about AI replication of their skills and personalities, leading to fears of losing professional identity. Meanwhile, the White House and Anthropic are working on a compromise, and other tech news includes Palantir's manifesto, Germany's push for looser AI rules, and Nvidia's shift towards AI over gaming.

MIT Technology Review•
MIT Technology Review

What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma

Moderna is facing a dilemma over whether to call its cancer treatment a "vaccine" or a "therapy" to distance itself from vaccine skepticism. The company's mRNA technology is being used in partnership with Merck to develop individualized neoantigen therapy for cancer treatment. Despite the promising results, some are concerned that patients may be misled by the terminology change. Moderna's strategy to rebrand its cancer treatment may be a response to government scrutiny over its mRNA vaccines. The debate over terminology reflects the broader challenges in navigating public perception and regulatory hurdles in the biotech industry.

MIT Technology Review•
MIT Technology Review

The Download: brainless human clones and the first uterus kept alive outside a body

A California-based startup, R3 Bio, has revealed plans to create brainless monkey “organ sacks” for medical testing and potentially backup human bodies. In another breakthrough, researchers kept a donated human uterus alive outside the body using a device called “Mother,” raising possibilities for extended womb maintenance and even fetal growth. Additionally, AI data centers are found to significantly warm surrounding areas, while tech stocks face challenges amid the Iran war and legal disputes. Meta is set to launch new smart glasses for prescription wearers, and Taiwan is investigating Chinese firms for tech talent poaching.

MIT Technology Review•

We use cookies

We use cookies to ensure you get the best experience on our website. For more information on how we use cookies, please see our cookie policy.